What's new

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 18, Status: Authorised

Apr 9, 2025 - 15:59
 0
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 18, Status: Authorised
Read More

Tags:

Previous Article

Solvay advances European rare earths production through capacity expansion

Next Article

Minutes of the PRAC meeting 10-13 February 2025

Related Posts

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

EMEA-003420-PIP01-23

EMEA-003420-PIP01-23

Apr 14, 2025  0

Human medicines European public assessment report (EPAR): Penbraya, Meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed), Date of authorisation: 14/11/2024, Status: Withdrawn

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0